Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: SOC plus Placebo IV Clear all

Conditions: COVID-19
Interventions: Brilacidin, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Winfield, Illinois • Toledo, Ohio

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001, Placebo (NNC6019-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 63
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more

Conditions: Generalized Pustular Psoriasis
Interventions: Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab, Standard of Care (SOC), Imsidolimab 750 mg IV/200 mg SC; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo; Drug · Biological · Other
Lead sponsor: Donald T. Weed, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions: Placebo, SHP655, Standard of Care; Other · Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Influenza A, Influenza B
Interventions: Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more

Conditions: Autoimmune Hepatitis, AIH
Interventions: Inebilizumab, Placebo, Standard of Care; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 12
States / cities: Little Rock, Arkansas • Rialto, California • Valencia, California + 9 more

Conditions: COVID-19
Interventions: BRII-196, BRII-198, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 76
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more

Conditions: Multiple Myeloma
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: COVID-19
Interventions: LY3819253, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 42
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more

Conditions: Covid-19
Interventions: CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 13
States / cities: Chula Vista, California • El Centro, California • La Mesa, California + 10 more

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 63
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more

Conditions: Malignant Digestive System Neoplasm
Interventions: Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration; Procedure · Drug · Device + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: CF-301, Placebo; Biological · Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration; Drug · Procedure · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 41
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more

Conditions: COVID-19
Interventions: SOC + Intravenous Famotidine, SOC + Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 347
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more

Conditions: Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions: Niraparib, Dostarlimab (TSR-042), Standard of care, Dostarlimab-Placebo, Niraparib-Placebo; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 65
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions: Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care; Drug
Lead sponsor: APR Applied Pharma Research s.a.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Fullerton, California • Irvine, California • Miami, Florida + 6 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Multi-site Adaptive Trials for COVID-19

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure